U
HBIO icon

UBS’s Harvard Bioscience HBIO Stock Holding History

UBS’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,161
Closed -$41K – 10495
2013
Q2 		$41K Buy
+1,161
New +$44.4K ﹤0.01% 6977

Other funds holding HBIO

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

UBS's HBIO Position: Q3 2014 in Review

UBS increased its Harvard Bioscience (HBIO) stake by 630% in Q3 2014, buying an estimated $5.79K and bringing the position to 146 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #9279.

UBS first reported a position in HBIO in Q2 2013 and has held it in 6 quarters since. The position peaked at $49K in Q3 2013. 72 funds tracked by Wall St. Rank hold HBIO as of Q3 2014.

  • UBS held 146 shares of Harvard Bioscience worth $6K as of Q3 2014.
  • UBS bought 126 Harvard Bioscience shares in Q3 2014, an estimated $5.79K.
  • Harvard Bioscience made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9279 holding.
  • UBS first reported a position in Harvard Bioscience in Q2 2013 and has held it in 6 quarters since.
  • UBS's Harvard Bioscience position peaked at $49K in Q3 2013.
  • 72 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.